Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05933148 · ClinicalTrials.gov registry record · NA

Network Neurofeedback Using 7-Tesla MRI to Reduce Rumination Levels in Depression

A NA study of Major Depressive Disorder, sponsored by Icahn School of Medicine at Mount Sinai.

Recruiting
Registry status
NA
Development phase
80
Enrollment target
1
Study location

NCT05933148: Recruiting NA study of Major Depressive Disorder, sponsored by Icahn School of Medicine at Mount Sinai.

NCT05933148 is a NA study of Major Depressive Disorder that is actively recruiting participants, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 80 participants, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05933148, a NA study of Major Depressive Disorder, is actively recruiting participants, sponsored by Icahn School of Medicine at Mount Sinai.

RECRUITING
Registry status
NA
Development phase
80 participants
Enrollment target
1
Study location

Study Summary

Patients with major depressive disorder (MDD) exhibit increased levels of rumination (i.e. repetitive thinking and focus on negative mood states) which have been found to increase the risk of depressive relapse. The ability to reduce rumination levels among these patients is greatly needed. Rumination is known to be associated with the default mode network (DMN) region activity. Implementing the Dependency Network Analysis (DEPNA), a recently developed method by the research team to quantify the connectivity influence of network nodes, found that rumination was significantly associated with lower connectivity influence of the left medial orbitofrontal cortex (MOFC) on the right precuneus, both key regions within the DMN. This study implements the first real-time fMRI neurofeedback (Rt-fMRI-NF) network-based protocol for up-regulation of the MOFC influence on the precuneus in patients with MDD to reduce rumination levels. This will allow for more accurate explicit brain connections modulation than the standard single brain region activity; creating a larger opportunity for target clinical neuromodulation treatment in individuals with MDD.

Conditions Studied

Interventions

  • DEVICE Siemens 7T MRI
  • DEVICE Sham Neurofeedback

Study Locations (1)

New York

  • Icahn School Of Medicine at Mount Sinai - New York

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2023-07-12
Est. Completion 2027-04
Phase NA

What NCT05933148 shows while recruiting

NCT05933148 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (79% lower).

The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 2 interventions - of which Siemens 7T MRI is the first listed.

NCT05933148 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT05933148 about?

NCT05933148 is a clinical study titled "Network Neurofeedback Using 7-Tesla MRI to Reduce Rumination Levels in Depression". Patients with major depressive disorder (MDD) exhibit increased levels of rumination (i.e. repetitive thinking and focus on negative mood states) which have been found to increase the risk of depressive relapse. The ability to reduce rumination levels among these patients is greatly needed. Ruminati...

What is the current status of trial NCT05933148?

This trial is currently recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2023-07-12. Estimated completion is 2027-04.

What conditions does trial NCT05933148 study?

This clinical trial studies the following conditions: Major Depressive Disorder.

What interventions are being tested in trial NCT05933148?

The interventions under investigation include: Siemens 7T MRI (DEVICE), Sham Neurofeedback (DEVICE).

Who is sponsoring clinical trial NCT05933148?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05933148 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Major Depressive Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05933148's enrollment target sits among peer trials

80 143rd of 282 higher than 134 of 282 other Major Depressive Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Major Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01243931 · 80 participants · NA

    Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy

  • NCT01659203 · 80 participants · Phase 1

    Proton or Photon RT for Retroperitoneal Sarcomas

  • NCT01803451 · 80 participants · Early Phase 1

    Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

  • NCT01964859 · 80 participants · Phase 2

    Feasibility Study for Fibroblast Autologous Skin Grafts

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05933148, the US trial registry maintained by the National Library of Medicine. NCT05933148 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.